Tallac Therapeutics

14 articles about Tallac Therapeutics

• Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

  4/10/2024

  Tallac Therapeutics, Inc., a privately held clinical stage biopharmaceutical company pioneering the discovery and development of novel antibody-oligonucleotide conjugates, today announced the presentation of preclinical data demonstrating TAC-001 potentiates cancer vaccine efficacy and rejuvenates vaccine responses.

• Tallac Presents First Clinical Data for TAC-001 at SITC 2023

  11/3/2023

  Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, announced the first presentation of TAC-001 Phase 1 clinical safety and efficacy data in solid tumor patients.

• Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

  9/27/2023

  Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the acceptance of two abstracts (related to TAC-001 and TAC-003) at the SITC 38th Annual Meeting in San Diego, CA, from November 3-5, 2023.

• Horizon Technology Finance Provides $15 Million Venture Loan Facility to Tallac Therapeutics

  8/2/2023

  Horizon Technology Finance Corporation announced it has provided a $15 million venture loan facility to Tallac Therapeutics, Inc., of which $5 million has been initially funded.

• Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer

  1/19/2023

  Tallac Therapeutics, Inc. today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.

• Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting

  11/11/2022

  Tallac Therapeutics, Inc. today announced that the Company presented data for two, first-in-class toll-like receptor 9 (TLR9) agonist antibody conjugates from its novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022).

• Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors

  7/28/2022

  Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors.

• Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors

  5/19/2022

  Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to study TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors.

• Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer

  4/15/2021

  Tallac Therapeutics, Inc. (“Tallac”), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer

• Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American Association for Cancer Research (AACR)

  4/10/2021

  TAC-001, Tallac’s lead candidate from novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform, induces innate and adaptive immune responses that generate potent anti-tumor activity in preclinical study

• Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

  3/23/2021

  Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service Agreements

• ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

  3/4/2021

  Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRPα antibody conjugated to TLR9 agonist (“SIRPα TRAAC”) that delivers targeted immune activation

• 

  Biopharma Money on the Move: November 25 – December 1

  12/2/2020

  A roundup of which pharma and biotech companies are grabbing cash before the 2020 calendar closes.

• Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer

  12/1/2020

  Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the completion of its Series A financing totaling $62 million.